Patent · US Active

Use of a genetically modified infectious measles virus with enhanced pro-apoptotic properties (MV-deltaC virus) in cancer therapy

US10314905B2 · kind B2 · utility

1Cited by

2References

6Claims

0Family size

Assignees

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
INSTITUT PASTEUR · FR
UNIVERSITE DE NANTES · FR

Inventors

Frédéric Tangy · Les Lilas, FR
Marc Gregoire · Nantes, FR
Jean-François Fonteneau · Nantes, FR
Jean-Baptiste Guillerme · Nantes, FR
Chantal Combredet · Paris, FR

Key dates

Filing date	Jan 25, 2018
Grant date	Jun 11, 2019
Priority date	—
Expiry date	Jan 25, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18462
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.